Tirzepatide for HFPEF and Obesity - SUMMIT - Prof. Dr. Barry A Borlaug (Rochester, MN, USA) скачать в хорошем качестве

Tirzepatide for HFPEF and Obesity - SUMMIT - Prof. Dr. Barry A Borlaug (Rochester, MN, USA)

Professor Barry Borlaug presents the SUMMIT trial on the use of the GIP / GLP-1 receptor dual agonist in patients with obesity-associated Heart-Failure with Preserved Ejection Fraction, which has been published in New Engl J Med 2024 and elected the most important study in cardiology and lipidology 2024 by MARKUS at HOMe. Dr. Borlaug is Professor of Medicine and Director, Circulatory Failure Research, Division of Cardiovascular Diseases, and Chair for Research, Division of Circulatory Failure, Department of Cardiovascular Medicine at the Mayo Clinic, Rochester, Minnesota. He is a global leader in studies on mechanisms, diagnosis and treatment of heart failure, particularly heart failure with preserved ejection fraction (HFPEF). The interview was recorded on January 16th, 2025. Moderators: Prof. Dr. Dr. Stephan Schirmer (Kaiserslautern, Germany), Prof. Dr. Florian Custodis (Saarbrücken, Germany) and Prof. Dr. Gunnar Heine (Frankfurt, Germany). Articles discussed: GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Leggio L, Hendershot CS, Farokhnia M, Fink-Jensen A, Klausen MK, Schacht JP, Simmons WK. Nat Med 2023 doi: 10.1038/s41591-023-02634-8 Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy. Kramer CM, Borlaug BA, Zile M MR, Ruff D, DiMaria JM, Menon V, Ou Y, Zarante AM, Hurt KC, Murakami M, Packer M; SUMMIT Trial Study Group. J Am Coll Cardiol 2024 doi: 10.1016/j.jacc.2024.11.001 Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, Hurt KC, Murakami M, Borlaug BA; SUMMIT Trial Study Group. N Engl J Med 2024 doi: 10.1056/NEJMoa2410027 Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Borlaug BA, Zile MR, Kramer CM, Baum SJ, Hurt K, Litwin SE, Murakami M, Ou Y, Upadhyay N, Packer M. Nat Med 2024 doi: 10.1038/s41591-024-03374-z Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Circulation 2017 doi: 10.1161/CIRCULATIONAHA.116.026807 An evidence-based screening tool for heart failure with preserved ejection fraction: the HFpEF-ABA score. Reddy YNV, Carter RE, Sundaram V, Kaye DM, Handoko ML, Tedford RJ, Andersen MJ, Sharma K, Obokata M, Verbrugge FH, Borlaug BA. Nat Med 2024 doi: 10.1038/s41591-024-03140-1 A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. Circulation 2018 doi: 10.1161/CIRCULATIONAHA.118.034646 How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. Eur J Heart Fail 2020 doi: 10.1002/ejhf.1741 Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial. Tada A, Burkhoff D, Naser JA, Harada T, Pourmussa B, Reddy YNV, Jensen MD, Carter RE, Demmer RT, Testani JM, Chirinos JA, Borlaug BA. Circulation 2024 doi: 10.1161/CIRCULATIONAHA.124.068788 Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial. Borlaug BA, Reddy YNV, Braun A, Sorimachi H, Omar M, Popovic D, Alogna A, Jensen MD, Carter R Circulation 2023 doi: 10.1161/CIRCULATIONAHA.123.065134